Sage Journals: Discover world-class research

Abstract

A multiplex amplification refractory mutation system reverse transcription polymerase chain reaction (ARMS RT-PCR) was developed for the differential diagnosis of Feline leukemia virus (FeLV) vaccine and wild-type strains based on a point mutation between the vaccine strain (S) and the wild-type strain (T) located in the p27 gene. This system was further upgraded to obtain a real-time ARMS RT-PCR (ARMS qRT-PCR) with a high-resolution melt analysis (HRMA) platform. The genotyping of various strains of FeLV was determined by comparing the HRMA curves with the defined wild-type FeLV (strain TW1), and the results were expressed as a percentage confidence. The detection limits of ARMS RT-PCR and ARMS qRT-PCR combined with HRMA were 100 and 1 copies of transcribed FeLV RNA per 0.5 ml of sample, respectively. No false-positive results were obtained with 6 unrelated pathogens and 1 feline cell line. Twelve FeLV Taiwan strains were correctly identified using ARMS qRT-PCR combined with HRMA. The genotypes of the strains matched the defined FeLV wild-type strain genotype with at least 91.17% confidence. A higher degree of sequence polymorphism was found throughout the p27 gene compared with the long terminal repeat region. In conclusion, the current study describes the phylogenetic relationship of the FeLV Taiwan strains and demonstrates that the developed ARMS RT-PCR assay is able to be used to detect the replication of a vaccine strain that has not been properly inactivated, thus acting as a safety check for the quality of FeLV vaccines.

Keywords

multiplex amplification refractory mutation system polymerase chain reaction vaccine

Introduction

Since the initial discovery of the link with feline lymphosarcoma in 1964, Feline leukemia virus (FeLV), a member of the genus Gammaretrovirus, has become the most common nonaccidental cause of death among cats.^12,26 The virus infects domestic and wild cats sporadically, and a large number of the infected cats, particularly outbred individuals, will die within 4 years.^22,28 Cats can develop either a progressive or a regressive infection, and no differences have been observed in the initiation of both infections.¹⁷ The progressive infection leads to FeLV-associated diseases, including aplastic anemia, immunodeficiency, and hematopoietic malignancies.^1,7 Animals with regressive infection present undetectable or transient viremia and antigenemia.¹⁵ Based on the genetic polymorphism of the surface glycoprotein molecules of the envelope gene, 3 subgroups of FeLV, namely types A–C, have been identified.² Studies have indicated that the type B and type C FeLVs may arise from a recombination of the endogenous FeLV elements with an exogenous type A FeLV.³

Virus isolation remains the gold standard for the diagnosis of FeLV infection. Both a fluorescent antibody test (FAT) and an enzyme-linked immunosorbent assay (ELISA) against the p27 core protein are used, but the cats have to have been infected for 6 and 4 weeks to test positive, respectively.¹³ Polymerase chain reaction (PCR) and real-time PCR (qPCR) assays targeting the FeLV proviral DNA or RNA were developed for the diagnosis of FeLV.¹¹ Because positive results can be obtained less than 2 weeks after exposure, these molecular tests are considered sensitive approaches.¹⁶ The progressive infection is characterized by positive ELISA and FAT results and high plasma viral RNA or proviral DNA loads, whereas only a positive result for proviral DNA is often seen in the regressive infection.²⁷ Under certain conditions, including those found in discordant cats that present positive ELISA and negative FAT results and in those kittens that receive a maternal antibody that interferes with the detection of the FeLV antigen, the animals should be further considered sources for disease spread if they present positive PCR results.²⁷

To date, the vaccination of cats remains an important strategy against FeLV-associated diseases.¹⁸ Although different efficacies have been reported, recombinant subunit vaccines, canary-vectored recombinant vaccines, and inactivated whole virus vaccines are the most recommended.¹⁵ Even though vaccines cannot protect cats from an integration of proviral DNA and viral replications, less persistent viremia and FeLV-associated diseases and longer survival times have been observed.¹⁵ Therefore, repeated vaccination plans combined with a screening program appear to be beneficial to cat owners.³⁰ Accordingly, as well as potency, the control of the safety of inactivated FeLV vaccines has become a significant issue for both users and producers due to the unique lifecycle of FeLV.

While the FeLV-positive rate of sick cats based on ELISA and FAT was 13.1%, a rate of only 2.3% was found for random healthy cats in North America.¹³ The average positive rate for sick cats in Brazil and Canada is 16.4% and 6%, respectively, by ELISA.^5,20 The use of PCR for screening FeLV in Brazil revealed positive rates for sick cats and healthy cats of 47.2% and 47.4%, respectively.⁵ The positive rate obtained in a survey conducted in Spain was 35.7% by ELISA.¹⁰ The FeLV-positive rate of cats in Brazil by PCR is consistent with the average prevalence of 30–40% found worldwide because PCR can detect the proviral DNA in FeLV-infected cats, which may not exhibit soluble antigens during the test.¹⁷ At present, no information is available on the prevalence of FeLV in Taiwan.

Single nucleotide polymorphisms (SNPs) are found in different individual isolates, and these changes account for sequence variations among these isolates. Such SNPs are useful for differential diagnosis because most DNA markers are based on genetically stable areas of the genome.³³ Since 2011, both multiplex amplification refractory mutation system reverse transcription polymerase chain reaction (ARMS RT-PCR) and high-resolution melt analysis (HRMA) have been used for SNP analysis. These procedures exhibit several advantages, including the ability to check at least 10⁴ samples in 5 working days, wide availability, and rapid turnaround time.^19,33 When specific terminal 3′-nucleotides are included in the primers, ARMS RT-PCR can selectively amplify the respective alleles.^4,24 This procedure has been used for the differentiation of wild-type and vaccine strains of Canine distemper virus.⁵ High-resolution melt analysis comprises both qRT-PCR and melting curve analysis.⁶ The melting curve is generated by the denaturation of DNA amplicons in response to a gradual temperature change. Using fluorescent dyes, such as SYBR Green and EvaGreen, the melting temperature (Tm) and the shape of the melting curve can be used to discriminate allelic variations.⁹

The aim of the current study was to analyze the nucleotide sequences of the long terminal repeat (LTR) and the p27 genes of Taiwan isolates of FeLV and 2 contemporary vaccines. Based on point mutations inferred from the above analysis, both ARMS RT-PCR and ARMS qRT-PCR with HRMA protocols were developed for the differential diagnosis of field isolates and vaccine strains. Such approaches can be used to detect the replication of a vaccine strain that has not been properly inactivated.

Materials and methods

Sample collection and analysis

A total of 55 blood samples from sick cats admitted to local veterinary clinics around Taiwan were transported to the molecular diagnostic laboratory of the Department of Veterinary Medicine of National Chung Hsing University. The LTR gene, which is located in an exogenous FeLV element, and the p27 gene were sequenced for phylogenetic analysis.

P27 immunochromatography analysis

One hundred and fifty microliters of blood in 0.25 mg of ethylenediamine tetra-acetic acid (EDTA) were mixed with the horseradish peroxidase–labeled anti-FeLV antigen conjugate, and the mixture was then analyzed using a commercial kit^a according to the manufacturer’s instructions.

Isolation of DNA and RNA from white blood cells

Genomic DNA was extracted using a commercial kit^b according to the manufacturer’s instructions. Three hundred microliters of blood in 0.5 mg of EDTA were mixed with 1 ml of TRIzol reagent.^c After a 5-min incubation, 200 μl of chloroform was added to the lysate. After centrifugation, the supernatant was mixed with an equal volume of isopropanol and then stored at −70°C overnight. After centrifugation, the RNA was pelleted and dissolved in diethylpyrocarbonate (DEPC)-treated double-distilled water (DDW).

Polymerase chain reaction primers

The FeLV-U3-F(1), FeLV-G-R(1), FeLV-U3-F(2), and FeLV-G-R(2) primers were exactly as described in a previous report (Table 1).²³ The P27 OF 744, P27 OR 744, P27 IF 744, and P27 IR 744 primers were designed after multiple alignments of the p27 gene of FeLV. After the p27 genes from vaccine SP and P strains and wild-type strains of FeLV (TW1–TW12) were sequenced, a point mutation was identified between the vaccine and wild-type strains. The P27 vaccine-F and P27 wild-R primers were designed to specifically target the vaccine and wild strains, respectively. Detailed information on the primers is shown in Figure 1 and Table 1.

Table 1.

Primers for the detection of Feline leukemia virus (FeLV).*

Primer name	Type	Sequence (5′–3′)	Nucleotide position	Reference
FeLV-U3-F(1)	Forward outer	ACAGCAGAAGTTTCAAGGCC	187–206	24
FeLV-G-R(1)	Reverse outer	GACCAGTGATCAAGGGTGAG	937–956	24
FeLV-U3-F(2)	Forward inner	GCTCCCCAGTTGACCAGAGT	225–244	24
FeLV-U3-R(2)	Reverse inner	GCTTCGGTACCAAACCGAAA	806–825	24
P27 OF 744	Forward outer	AAGGTGTTACCGCCTGATCCTTC	1324–1343	Current study
P27 OR 744	Reverse outer	TTCGTTAGTACTGAGTGCTGGGC	2515–2534	Current study
P27 IF 744	Forward inner	CCCTGCTGAAGAATCTCAAG	1473–1492	Current study
P27 IR 744	Reverse inner	GGCCAGAACTTTAGTCATCTC	2224–2244	Current study
P27 OF	Forward outer	ATCAACCAACCTGGGACGACTGCC	1640–1663	Current study
P27 OR	Reverse outer	GGGTGAACCCTTGTAGACCTTCTAGCC	2084–2110	Current study
P27 vaccine-F	ARMS inner	ACCCGTCCCAACTGGGATTTTGTS	1795–1818	Current study
P27 wild-R	ARMS inner	TGCTCCCTACCTGCCGGCGCA	1818–1838	Current study

ARMS = amplification refractory mutation system. The nucleotide position number was based on the sequence of GenBank accession no. AF052723.

Figure 1.

Regions of the Feline leukemia virus (FeLV) genome used for the design of the primers. For multiplex amplification refractory mutation system reverse transcription polymerase chain reaction (ARMS RT-PCR) and real-time ARMS RT-PCR (ARMS qRT-PCR) assays, the primer set of P27 OF 744 and P27 OR 744 was used for the first-round PCR. The 2 primer sets of P27 OF/P27 wild-R and P27 vaccine-F/P27 OR were used for the second-round ARMS RT-PCR and ARMS qRT-PCR. The P27 vaccine-F and P27 wild-R were used to differentially amplify the FeLV TW strains and the FeLV vaccine strains, respectively. The single nucleotide polymorphisms are S for the FeLV TW strains and T for the FeLV vaccine strains.

Polymerase chain reaction reverse transcription PCR, and cloning of sequence

The extracted RNA was heated to 65°C and then placed on ice. The first-strand complementary (c)DNA synthesis was performed in a total reaction volume of 12 μl containing 4 μl of 5× first-strand buffer, 2 μl of 0.1 M dithiothreitol, 1 μl of ribonuclease inhibitor (40 units/μl), 1 μl of M-MLV reverse transcriptase^d (200 units/μl), and 0.1 μM of oligo-dT primer at 37°C for 50 min and then inactivated at 70°C for 15 min. The PCR reaction was performed in a total reaction volume of 25 μl consisting of 2.5 μl of 10× buffer, 10 μM of each deoxyribonucleotide triphosphate (dNTP), 1.5 mM MgCl₂, 0.1 μM of the FeLV-U3-F(1) and FeLV-G-R(1) primers or the P27 OF 744 and P27 OR 744 primers, 0.5 μl of Taq polymerase^e (5 units/μl), and 3 μl of genomic DNA or cDNA. The PCR conditions were 95°C for 5 min, 35 cycles of denaturation at 95°C for 30 sec, annealing at 50°C for 30 sec, and extension at 72°C for 1 min, and a final extension at 72°C for 10 min. The second PCR was performed using the aforementioned conditions with the following change: the FeLV-U3-F(2) and FeLV-G-R(2) primers or the P27 IF 744 and P27 IR 744 primers were used. Five microliters of the products from the second PCR were analyzed in a 2% agarose gel. For sequencing, the products from the second PCR of the LTR and p27 genes were purified, cloned into a commercial vector,^f and transformed into Escherichia coli DH5α cells^g according to the manufacturer’s instructions. The positive clones were sent for sequencing analysis on both directions. A standard plasmid, p-TEasy-p27, was constructed through the insertion of the p27 gene fragment generated using the P27 OF 744 and P27 OR 744 primers into a commercial vector.^f

In vitro transcription of FeLV plasmid

The viral RNA was produced using a commercial kit^h according to the manufacturer’s instructions. Two micrograms of p-TEasy-p27 plasmids were linearized with the HincCII enzymeⁱ and then incubated at 37°C for 1 hr with 0.5 mM nucleoside triphosphates, 10 mM dithiothreitol, 0.2 U/ml of RNase inhibitor, and 5 U/ml of T7 RNA polymerase. After DNase I treatment, the RNA was extracted with acidic phenol and precipitated with an equal volume of isopropanol at −70°C overnight. After centrifugation, the RNA was pelleted and dissolved in DEPC-treated DDW. The concentration of RNA was measured spectrophotometrically, assuming that 1 unit of OD₂₆₀ equals 40 mg/ml, and the copy number was calculated.

Amplification refractory mutation system RT-PCR and ARMS qRT-PCR combined with high-resolution melt analysis

The cDNA was amplified using a PCR program similar to that described above with the P27 OF 744 and P27 OR 744 primers and then subjected to ARMS RT-PCR in a total reaction volume of 25 μl containing 0.1 μM P27 OF, P27 OR, P27 vaccine-F, and P27 wild-R primers; 5 μl of the PCR products; 2.5 μl of 10× buffer; 10 μM of each dNTP; 1.5 mM MgCl₂; and 0.5 μl of Taq polymerase^e (5 units/μl). The PCR program was 95°C for 5 min, 35 cycles of denaturation at 95°C for 30 sec, annealing at 58°C for 30 sec, and extension at 72°C for 1 min, and a final extension at 72°C for 10 min. For ARMS qRT-PCR, the PCR mixture contained 0.1 μM P27 OF, P27 OR, P27 vaccine-F, and P27 wild-R primers; 12.5 μl of PCR master mix^j; and 5 μl of the PCR products. The PCR program was 95°C for 5 min and 35 cycles of denaturation at 95°C for 30 sec, annealing at 59.5°C for 30 sec, and extension at 72°C for 1 min. After qRT-PCR, HRMA was immediately performed, and the PCR products were melted from 69°C to 95°C at a rate of 0.05°C/sec. The melting profiles were analyzed using a commercial software^k for the generation of a high-resolution melt (HRM) algorithm. The highest and lowest fluorescence values were set to 100 and 0, respectively, to draw a best-fit line to normalize the raw data. The analysis was performed using normalization regions between 78°C and 88°C. The wild-type FeLV (TW1) was assigned as a “genotype,” and the HRM genotype confidence percentage (confidence %), which was defined as the similarity between the strain of interest and the representative genotype, was calculated. If necessary, the Tm for each sample was demonstrated.

Sensitivity and specificity of ARMS RT-PCR and ARMS qRT-PCR

To determine the sensitivity, a series of 10⁶, 10⁵, 10⁴, 10³, 10², 10, and 1 copies of transcribed FeLV, which represent the copy number for each strain in the mixed templates (the FeLV P vaccine, FeLV SP vaccine, and FeLV TW strains) per 0.5 ml of sample, were examined by ARMS RT-PCR. Using the ARMS qRT-PCR protocol, 10⁴, 5 × 10², 50, 5, and 1 copies of transcribed FeLV, which represent the copy number for each strain in the mixed templates (the FeLV P vaccine, FeLV SP vaccine, and FeLV TW strains) per 0.5 ml of sample, were also tested. A no-template control (NTC) was included. To determine the specificity, the cDNA from the mixture of P vaccine, SP vaccine, and Taiwan strains of FeLV, Feline immunodeficiency virus (FIV), Feline infectious peritonitis virus (FIPV), Crandell feline kidney (CRFK) cells, feline viral rhinotracheitis (FVR), Feline calicivirus (FCV), Feline panleukopenia virus (FPV), and Chlamydia psittaci were tested by ARMS RT-PCR and ARMS qRT-PCR assays.

Phylogenetic analysis

The background information of the cats that tested positive for FeLV is shown in Table 2. For the phylogenetic analysis, the LTR and p27 genes from different FeLV strains available in GenBank were included. For the LTR gene analysis, the GenBank accession numbers of the FeLVs included were AB18756, AY364318, AY364319, AY745878, DQ821502, EU48346, EU48348, EU48351, EU48352, EU048356, EU048362, EU048365, EU090946, and M18247. These sequences were compared with the FeLV TW1–TW12, P vaccine, and SP vaccine strains. For the p27 gene, the FeLV TW1–TW12, P vaccine, and SP vaccine strains were compared with the following FeLV GenBank accessionnumbers: AB052723, AB060732, AB187565, AB672612, ABAB673426, AB673427, AB673431, AY364318, AY364319, FCVF6A, JF957361, JF957363, K01643, K01803, M18247, and NC001940. The nucleotide sequences were aligned and edited using the CLUSTALW algorithm of a commercial software.^l For each strain pair, the identity and divergence percentages of both the FeLV and p27 genes were calculated. The phylogeny of the aligned nucleotides was analyzed using both the neighbor-joining and the Bayesian methods of a commercial software.^l A resampling of the original dataset with a thousand replications was conducted to obtain the bootstrap value. The 50% majority rule consensus tree was constructed through a Bayesian analysis based on the clade credibility value. The mortality rates for cats in clade I and clade II in the current study period were analyzed using the χ² test.

Table 2.

Background information on cats that tested positive for Feline leukemia virus in the current study.*

Sample name	Sex	Collection date	Breed	Symptoms
TW1	Male	2010/6/13	Mix	NA
TW2	Female	2011/6/9	Mix	Pale mucous membrane, pulmonary edema, hospitalize
TW3	Female	2011/7/1	Mix	Normal
TW4	NA	2011/8/8	NA	NA
TW5	Female	2011/8/19	Mix	Anemia
TW6	Female	2011/9/22	Siamese cat	Swollen lymph node
TW7	Female	2012/2/10	Mix	Normal
TW8	Male	2012/6/7	Mix	NA
TW9	Female	2012/8/3	Mix	Anemia, trouble breathing, pleural effusion, hospitalize
TW10	Male	2012/10/3	Mix	NA
TW11	Female	2013/4/16	Persian cat	Ascites
TW12	Male	2013/5/3	Mix	Fever, lethargy

NA = not available.

Results

Samples detected by PCR and p27 immunochromatography and sequence analysis for the design of ARMS RT-PCR primers

Among 55 samples, 12 samples were positive by both the p27 immunochromatography assay and PCR. The partial LTR sequence of exogenous FeLV (nucleotides 1473–2244) was amplified from the above positive samples, named as TW1–TW12 strains, and from the P and SP vaccine strains. All of the LTR sequences were submitted to GenBank, and the accession numbers for TW1–TW12, and the P and SP vaccine strains were KF736909–KF736920 and KF792076, and KF792075, respectively. The GenBank accession numbers for the p27 genes of TW1–TW12, and the P and SP vaccine strains were KF736921–KF736932 and KF792078, and KF792077, respectively. After the sequences were aligned, a T at position 321 was found in all of the TW strains, whereas a G and C were observed in the SP vaccine and P vaccine strains, respectively. Therefore, 2 pairs of ARMS RT-PCR primers were designed for allelic discrimination. The most abundant 3′-termini of the inner primers for the vaccine and TW strains were S and T, respectively. An additional mismatch included 2 bases from the 3′-termini to destabilize the primers (Fig. 1).

Sensitivity of ARMS RT-PCR and ARMS qRT-PCR

The detection limit of the ARMS RT-PCR assay was 10² copies of transcribed FeLV per 0.5 ml of sample. No amplicons were observed in the negative control (Fig. 2A). In the ARMS qRT-PCR, sigmoid curves composed of both an exponential rise and a plateau characterized productive amplifications. The threshold cycle (Ct) values for 10⁴, 5 × 10², 50, 5, and 1 copies of transcribed FeLV per 0.5 ml of sample were 29.45, 32.77, 33.75, 34.58, and 36.26. No amplification of the NTC was found. The findings suggest that the detection limit of ARMS qRT-PCR was 1 copy of transcribed FeLV per 0.5 ml of sample (Fig. 2B). Taken together, the results demonstrate that the sensitivity of the ARMS qRT-PCR assay is 100-fold higher than that of ARMS RT-PCR.

Figure 2.

A, sensitivity of multiplex amplification refractory mutation system reverse transcription polymerase chain reaction (ARMS RT-PCR). Lane M: 100-bp DNA markers; lanes 1–6: 10⁶, 10⁵, 10⁴, 10³, 10², 10, and 1 copies of transcribed Feline leukemia virus (FeLV) RNA, respectively; lane 7: negative control. B, sensitivity of real-time ARMS RT-PCR. 10⁴, 5×10², 50, 5, and 1 copies of transcribed FeLV RNA were analyzed. The y-axis and x-axis represent the fluorescence strength and the cycle number, respectively.

Specificity of ARMS RT-PCR and ARMS qRT-PCR

The amplification of a mixed sample of the P vaccine, SP vaccine, and TW strains using ARMS RT-PCR resulted in 3 fragments of 470, 315, and 198 bp. This finding suggests that the P vaccine, SP vaccine, and TW strains were successfully amplified. No amplification of RNA from feline pathogens and cells, including FIV, FIPV, CRFK, FVR, FCV, FPV, and C. psittaci, was found, thereby proving the specificity of the assay (Fig. 3A). Melting peaks derived from productive amplifications using ARMS qRT-PCR were only observed for the TW strains, P vaccine strain, SP vaccine strain, and a mixed sample of P vaccine, SP vaccine, and TW strains (Fig. 3B). The Tm values for the SP vaccine strain, P vaccine strain, and the mixed sample were 86.77°C, 86.8°C, and 86.43°C, respectively. However, a double-peaked melting curve with a broad front peak (Tm value of 86.77°C) higher than the later peak (Tm value of 87.25°C) was obtained for the TW strains, which indicates that, even though no obvious differences were observed in the Tm values of the P and SP vaccine strains, the TW strains can be readily differentiated from the other strains (Fig. 3C). In the normalized melting curve, the fluorescence transition patterns of the TW strain, the P vaccine strain, and the SP vaccine strain were different. However, in contrast, no differentiation was possible when a mixed sample of the P vaccine, SP vaccine, and TW strains was compared to the TW strain alone (Fig. 3D). A broad melting curve and no apparent fluorescence transition were observed for FIV, FIPV, CRFK, FVR, FCV, FPV, and C. psittaci due to the lack of amplification (Fig. 3D). No melting peak and fluorescence transition were observed in the NTC further validating the specificity of this assay (Fig. 3B, 3D). This finding demonstrates that the specificity of the ARMS qRT-PCR assay is superior to that of ARMS RT-PCR in terms of differentiating the P and SP vaccine strains.

Figure 3.

A, specificity of multiplex amplification refractory mutation system reverse transcription polymerase chain reaction (ARMS RT-PCR). Lane M: 100-bp DNA markers; lanes 1–8: Feline leukemia virus (FeLV) TW and FeLV vaccine strains, FIV, FIPV, CRFK cells, FVR, FCV, FPV, and Chlamydia psittaci, respectively. B, specificity of real-time ARMS RT-PCR (ARMS qRT-PCR). Plot of the first derivative of the fluorescence (dF/dT) as a function of the melting temperature. C, melting temperatures of the ARMS qRT-PCR products amplified from SV, PV, WT, and MIX. D, plot of the normalized fluorescence as a function of the melting temperature. PV = FeLV P vaccine strain; SV = FeLV SP vaccine strain; WT = FeLV TW strain; Mix = FeLV TW and vaccine strains; FIV = Feline immunodeficiency virus; FIPV = Feline infectious peritonitis virus; CRFK = Crandell feline kidney; FVR = feline viral rhinotracheitis; FCV = Feline calicivirus; FPV = Feline panleukopenia virus; Chla. psi. = Chlamydia psittaci; NTC = no template control.

Clinical samples detected by ARMS RT-PCR and ARMS qRT-PCR

Positive results were only obtained by ARMS RT-PCR for cases TW1–TW12 among the 55 samples tested. Two fragments of 470 and 198 bp were obtained, which suggests that these samples are FeLV wild-type strains (Fig. 4). The confidence percentage values of TW1–TW12 ranged from 91.17% to 97.43%, as determined using ARMS qRT-PCR combined with HRMA (Table 3). This finding further validated that all of the samples were FeLV wild-type strains.

Figure 4.

Results of the clinical samples including Feline leukemia virus (FeLV) TW1–TW12 detected by multiplex amplification refractory mutation system reverse transcription polymerase chain reaction. Lane M: 100-bp DNA markers.

Table 3.

Feline leukemia virus (FeLV) genotype and confidence percentage (confidence %) of clinical samples by real-time multiplex amplification refractory mutation system reverse transcription polymerase chain reaction.

Sample no.	Clinical sample	Genotype	Confidence %
1	Mix of P vaccine, SP vaccine, and TW strains	Mix	61.05
2	TW1	Wild type	100
3	SV	Variation	27.68
4	PV	Variation	26.9
5	TW1	Wild type	96.77
6	TW2	Wild type	97.43
7	TW3	Wild type	97.42
8	TW4	Wild type	94.46
9	TW5	Wild type	92.75
10	TW6	Wild type	91.17
11	TW7	Wild type	93.15
12	TW8	Wild type	91.24
13	TW9	Wild type	94.96
14	TW10	Wild type	94.53
15	TW11	Wild type	93.49
16	TW12	Wild type	92.12

Phylogenetic analysis of FeLV vaccine and FeLV TW strains

The sequence identities among the LTR genes from the different TW strains ranged from 96.7% to 100%, but the identity between the LTR gene of the P vaccine strain and the LTR gene of the SP vaccine strain was 95.5% (data not shown). The comparison of the LTR genes from the TW strains with that of the P vaccine strain or that of the SP vaccine strain revealed identity ranges of 97.1–99.7% and 94.8–98.8%, respectively (data not shown). The LTR gene of the P vaccine strain instead of the SP vaccine strain was more closely related to the TW strain. They are clustered in the same group with a bootstrap value of 81. The nucleotide sequences of the LTR genes of the TW strains, vaccine strains, and strains from different countries were analyzed. The neighbor-joining tree indicated that all of the strains were distinct from endogenous FeLVs. Consistent with the above-mentioned sequence identity, the SP vaccine strain had a closer phylogenetic relationship with the FeLV Brazil strains (GenBank accession nos. EU048356 and EU048362; Fig. 5A). The topology of the Bayesian tree of the FeLV LTR phylogeny was highly similar with that of the tree obtained using the neighbor-joining method. The TW strains and the P vaccine strain were clustered in the same group with a clade credibility value of 0.95. A more detailed grouping of the TW strains and the P vaccine strain was observed with the Bayesian analysis. The TW2, TW4, TW7, and TW8 strains, P vaccine strain, and other TW strains were paraphyletic with a clade credibility value of 0.84. The P vaccine strain was closely related to the TW4 and TW7 strains, which are represented as a monophyletic group with a clade credibility value of 0.99 (Supplementary Fig. 1A; available online at http://vdi.sagepub.com/supplemental).

Figure 5.

A, the long terminal repeat region phylogeny of Feline leukemia virus (FeLV) TW strains, FeLV vaccine strains, and other FeLV strains based on the neighbor-joining method. The red and blue lines indicate the 2 major groups. The bootstrap values are shown at the nodes. B, the p27 gene phylogeny of FeLV TW strains, FeLV vaccine strains, and other FeLV strains based on the neighbor-joining method. The red, blue, and brown lines indicate the 3 major groups. The framed samples represent these animals died in the period of the current study. The TW strains are classified as clade I and clade II. The bootstrap values are shown at the nodes.

The sequence identities between the p27 genes from different TW strains ranged from 88.7% to 99.3%, and the identity between the p27 gene from the P vaccine strain and that of the SP vaccine strain was 95.2% (data not shown). A wider range of identities (88.7–99.3%) was found between the p27 genes of the TW strains and the vaccine strains (data not shown). Compared with the SP vaccine strain, the sequence identities between the p27 gene of the P vaccine and that of the FeLV Taiwan strains were higher. With respect to the p27 gene, the TW strains were clustered in 2 groups based on the neighbor-joining method. The P vaccine strain was more closely related with the TW7 strain, and these were clustered with the TW1, TW3, TW10, and TW11 strains. The SP vaccine strain formed an independent cluster with the type A FeLV strains from other countries. Even though some TW strains were placed in the clade that included both endogenous FeLVs (GenBank accession nos. EU048356 and EU048362), the TW4 strain was further separated from the remaining TW strains with a bootstrap value of 94 (Fig. 5B). The TW1, TW3, TW7, TW10, and TW11 strains and the P vaccine strain were separated from the other TW strains as monophyletic groups with a clade credibility value of 0.99, and both the TW7 strain and the P vaccine strain belonged to a subclade, as determined through Bayesian analysis. The TW4 strain was paraphyletic with other TW strains and both endogenous FeLVs but separate with a clade credibility value of 0.99. However, the endogenous FeLVs were further grouped as a subclade with a clade credibility value of 0.99 (Supplementary Fig. 1B; available online at http://vdi.sagepub.com/supplemental). No significant difference (P > 0.05) was found in the mortality of cats that formed clade I and clade II (Fig. 5B; Supplementary Fig. 1B; available online at http://vdi.sagepub.com/supplemental).

Discussion

The positive rate of the current study, which was based on 55 sick cats collected from 2010 to 2013 and which used proviral PCR, was 22%. This ratio is close to the lower value of the average prevalence of 30–40% previously reported.¹⁷ The positive rate of FeLV is largely determined by geographical location, lifestyle, and density of domestic and wild cats.¹⁰ In the island of Taiwan, a strict quarantine of imported cats from overseas, a higher rate of vaccination, and improved education campaigns may all lead to a reduced prevalence of the disease.¹⁰ In addition, it is not possible to exclude a bias in sampling because the samples tested were obtained from cats with suspected symptoms submitted by veterinarians that were usually sick due to secondary and opportunistic infections.¹⁴

To identify FeLV-infected cats, proviral PCR or RT-PCR is used depending on the objective. The PCR detection of the exogenous proviral DNA targets the FeLV sequences archived inside the cell genome.³³ These sequences may represent active viruses or silenced circulating viruses. The detection of proviral DNA facilitates an identification of asymptotic cats and also serves as the standard method for the sequence analysis of FeLV isolates to obtain an understanding of their phylogenetic relationship.⁵

In the present study, a RT-PCR was developed for the detection of the actively replicating virus, which may originate from viremia or the potential transcriptional reactivation of the integrated proviral DNA. The sensitivities of the RT-PCR and qRT-PCR assays were 100 and 1 viral copies per 0.5 ml of sample, respectively. It is noteworthy that an advantage of ARMS RT-PCR is its nested amplification, which can rapidly increase the template amounts for allelic-specific PCR through a simultaneous amplification of the target DNA by the outer primers.²¹ In addition, oligo-dT primers that specifically target the poly-A tail of FeLV are used to enhance the efficiency of the reverse transcriptions. The developed RT-PCR assay can also be used to detect FeLV in primary viremia at the early phase of infection before its integration into the genomic DNA and, most important, a local infection characterized by FeLV that only exists in local tissues instead of the bone marrow under strong immune pressure. Moreover, a previous study also indicated that, as long as a small amount of FeLV is integrated into the cells and then actively transcripted, the qRT-PCR assay can detect FeLV RNA even without the presence of an antigen, whereas ELISA would provide negative results.³¹ In the current study, 12 cats were tested positive by proviral PCR, ARMS RT-PCR, ARMS qRT-PCR, and p27 immunochromatography assay. Based on the progress of FeLV, these cats were likely exposed to FeLV more than 8 weeks prior to the study, which implies that the cats exhibit viremia, the presence of circulating FeLV, and proviral DNA in peripheral white blood cells.²⁹ It is noteworthy that, of the 12 cats, 4 cats (TW2, TW5, TW6, and TW9) were dead with clinical symptoms of FeLV-associated diseases.

Viral replication cannot be totally inhibited by contemporary vaccines, but these vaccines are able to protect cats from the development of FeLV-associated diseases.¹⁵ When vaccinated cats are exposed to FeLV, transient viremia may still occur (Sparkes AH: 2003, Feline leukemia virus and vaccination. Proceedings of the ESFE Feline Congress, Stockholm, September 2002. J Feline Med Surg 5:97–100). The most common vaccines are based on inactivated virus and are manufactured by different vendors with various adjuvants. Regardless of the content of the FeLV vaccines, type A FeLV is likely the background virus. Even though there is no available information on the spread of type B and type C FeLVs via a horizontal route, the productive infection of type B or type C FeLVs always occurs after recombination with type A FeLVs.³ However, a different subgroup of FeLV may still be used. This fact may explain why a closer relationship is only observed between the SP vaccine and type A FeLVs (GenBank accession no. M18247) in the LTR phylogeny. All of the FeLV TW strains and the FeLV P vaccine strain belong to a separate clade in the LTR phylogeny. Unlike vaccines for other viruses, safety control for assurance of an effective inactivation of retroviruses, such as FeLV, is a significant issue. To date, no differentiation of the FeLV vaccine and wild-type strains can be made using serology-based methods; however, the method developed in the current study, which is based on a genetic test, appears to be suitable for differentiation of vaccine and wild-type infections.

Even though all of the purine and pyrimidine mismatches on the 3′-terminal nucleotides of the ARMS RT-PCR primers are more refractory to extension, the primer/template S/T mismatches in the present study are less refractory to extension; thus, an additional mismatch was included 2 bases from the 3′-termini.²⁵ For destabilization of the ARMS RT-PCR primers and improvement of the specificity of the assay, the annealing temperature was increased to 58°C. In terms of sensitivity, specificity, and diagnostic capability, this assay is acceptable. To obtain a rapid process, a simple procedure, and a more accurate analysis with a quantitative standard, the ARMS qRT-PCR was developed. For quantitative purposes, different amounts of FeLV RNA, produced by in vitro transcription of FeLV plasmids, were amplified with samples in parallel. This single-step and closed-tube system is especially useful for SNP analysis. The EvaGreen dye, instead of the SYBR green dye, was used for HRM because the fluorescence reduction of the former in the beginning of the melting analysis is prone to be quenched.³² The discrimination of Tm based on the G + C content (%) can only be achieved between the vaccine strains and the TW strains but not between the SP vaccine strain (86.77°C) and the P vaccine strain (87°C). Furthermore, a model-free technique was applied to differentiate between different strains based on the shape of the melting curve. By including controls of all of the strains in each analyzed batch, the reproducibility of the results was confirmed. Based on the confidence percentages, the TW strains were successfully distinguished from the vaccine strains (at least 91.17% vs. 26.9%). This finding suggests an acceptable reliability as a differential diagnosis for the TW and vaccine strains. This type of ARMS qPCR assay has been used for the detection of SNPs of the BRAF and NRSF genes, and 2 sets of primer pairs are used to increase the complexity of the reaction. Thus, diverse products lead to a considerable change in the HRM patterns, which can be readily differentiated.^8,21 In the case of biopsied tumors, a mutant content as low as 1% in the normal background can be detected using this method, while a mutant content of at least 20% is required for detection by sequencing analysis.⁸ This finding is important because the ratio of FeLV RNA in the total RNA extracted from the peripheral blood mononuclear cells of FeLV-infected cats may not always be high.

Based on their LTR gene sequences, all of the FeLV TW strains and other exogenous FeLVs are clustered as a single clade and are monophyletic with endogenous FeLV. The LTR gene was selected as the target for phylogenetic analysis because the sequence variation in the LTR gene largely determines the tumorigenicity and outcome of the disease.² Based on the LTR phylogeny, the TW strains are clustered as an isolated group, and this finding was strongly supported by a clade credibility value of 0.95 from the Bayesian analysis. The result suggests that the TW strains exhibit a geographic characteristic. The p27 gene of FeLV not only encodes a major core protein but is a target for the detection of viremia. This gene may have a higher variation than the LTR gene under the pressure of an immune response. Two major clades were found for the TW strains. The strains in the upper clade including the P vaccine strain are paraphyletic. The strains are also paraphyletic with the p27 gene of endogenous FeLVs (GenBank accession nos. AY364318 and AY364319). Interestingly, 4 cats (TW2, TW5, TW6, and TW9) associated with clade II died, while only 1 cat (TW1) associated with clade I died prior to the end of the study. This possibly suggests a difference in pathogenicity between the clades; however, the number of positive samples is statistically insufficient for confident conclusions. In conclusion, the phylogenetic relationship of the FeLV Taiwan strains with other strains was reported. The developed ARMS RT-PCR assays were determined to be useful for the differentiation of the FeLV Taiwan strains and the FeLV vaccine strains.

Footnotes

Acknowledgements

The authors thank Dr. ML Wong for the guidance provided during this study.

a.

Snap combo feline leukaemia virus antigen/feline immunodeficiency virus antibody test kit, IDEXX Laboratories Inc., Westbrook, ME.

b.

EPICENTRE Biotechnologies, Madison, WI.

c.

MD Co., Taipei, Taiwan.

d.

Life Technologies, Grand Island, NY.

e.

Protech, Taipei, Taiwan.

f.

pGEM-T vector, Promega, Madison, WI.

g.

Promega Corp., Madison, WI.

h.

Riboprobe in vitro transcription systems, Promega Corp., Madison, WI.

i.

Promega Corp., Madison, WI.

j.

Type-it HRM PCR kit, Qiagen GmbH, Hilden, Germany.

k.

Rotor-gene Q series software, Qiagen GmbH, Hilden, Germany.

l.

DNASTAR Inc., Madison, WI.

Declaration of conflicting interests

The author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

Arjona

Barquero

Doménech

, et al.: 2007, Evaluation of a novel nested PCR for the routine diagnosis of feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV). J Feline Med Surg 9:14–22.

Bolin

Ahmad

Levy

: 2011, The surface glycoprotein of a natural feline leukemia virus subgroup A variant, FeLV-945, as a determinant of disease outcome. Vet Immunol Immunopathol 143:221–226.

Chen

Bechtel

Shi

, et al.: 1998, Pathogenicity induced by feline leukemia virus, Rickard strain, subgroup A plasmid DNA (pFRA). J Virol 72:7048–7056.

Chulakasian

Lee

Wang

, et al.: 2010, Multiplex amplification refractory mutation system polymerase chain reaction (ARMS-PCR) for diagnosis of natural infection with canine distemper virus. Virol J 7:122.

Coelho

Bomfim

de Andrade Caxito

, et al.: 2008, Naturally occurring feline leukemia virus subgroup A and B infections in urban domestic cats. J Gen Virol 89:2799–2805.

Cousins

Laeyendecker

Beauchamp

, et al.: 2011, Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One 6:e27211.

Daniels

Golder

Jarrett

MacDonald

: 1999, Feline viruses in wildcats from Scotland. J Wildl Dis 35:121–124.

Ellison

Donald

McWalter

, et al.: 2010, A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 29:132.

Erali

Voelkerding

Wittwer

: 2008, High resolution melting applications for clinical laboratory medicine. Exp Mol Pathol 85:50–58.

10.

Gleich

Krieger

Hartmann

: 2010, Selected highlights from other veterinary journals: changes in prevalence and risk factors for feline retroviral infections in Europe. Vet Rec 166:86.

11.

Gomes-Keller

Gönczi

Tandon

, et al.: 2006, Detection of feline leukemia virus RNA in saliva from naturally infected cats and correlation of PCR results with those of current diagnostic methods. J Clin Microbiol 44:916–922.

12.

Hardy

Jr Old

Hess

, et al.: 1973, Horizontal transmission of feline leukaemia virus. Nature 244:266–269.

13.

Hardy

Jr Zuckerman

: 1991, Ten-year study comparing enzyme-linked immunosorbent assay with the immunofluorescent antibody test for detection of feline leukemia virus infection in cats. J Am Vet Med Assoc 199:1365–1373.

14.

Hartmann

: 2011, Clinical aspects of feline immunodeficiency and feline leukemia virus infection. Vet Immunol Immunopathol 143:190–201.

15.

Hofmann-Lehmann

Cattori

Tandon

, et al.: 2007, Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up. Vaccine 25:5531–5539.

16.

Hofmann-Lehmann

Cattori

Tandon

, et al.: 2008, How molecular methods change our views of FeLV infection and vaccination. Vet Immunol Immunopathol 123:119–123.

17.

Jarrett

: 1999, Strategies of retrovirus survival in the cat. Vet Microbiol 69:99–107.

18.

Levy

Crawford

Hartmann

, et al.: 2008, 2008 American Association of Feline Practitioners’ feline retrovirus management guidelines. J Feline Med Surg 10:300–316.

19.

Lilliebridge

Tong

Giffard

Holt

: 2011, The utility of high-resolution melting analysis of SNP nucleated PCR amplicons—an MLST based Staphylococcus aureus typing scheme. PLoS One 6:e19749.

20.

Little

Sears

Lachtara

Bienzle

: 2009, Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in Canada. Can Vet J 50:644–648.

21.

Machnicki

Glodkowska-Mrowka

Lewandowski

, et al.: 2013, ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with real-time PCR-based techniques. Acta Biochim Pol 60:57–64.

22.

McClelland

Hardy

Jr Zuckerman

: 1980, Prognosis of healthy feline leukemia virus infected cats. In: Feline leukemia virus (developments in cancer research), ed. Hardy

WDJ

Essex

McClelland

, 1st ed., pp. 121–126. Elsevier, New York, NY.

23.

Miyazawa

Jarrett

: 1997, Feline leukaemia virus proviral DNA detected by polymerase chain reaction in antigenaemic but non-viraemic (‘discordant’) cats. Arch Virol 142:323–332.

24.

Newton

Graham

Heptinstall

, et al.: 1989, Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) Nucleic Acids Res 17:2503–2516.

25.

Newton

Heptinstall

Summers

, et al.: 1989, Amplification refractory mutation system for prenatal diagnosis and carrier assessment in cystic fibrosis. Lancet 2:1481–1483.

26.

Pedersen

Theilen

Keane

, et al.: 1977, Studies of naturally transmitted feline leukemia virus infection. Am J Vet Res 38:1523–1531.

27.

Pepin

Tandon

Cattori

, et al.: 2007, Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets of long-term experimentally infected cats. Virus Res 127:9–16.

28.

Roy-Burman

: 1995, Endogenous env elements: partners in generation of pathogenic feline leukemia viruses. Virus Genes 11:147–161.

29.

Tandon

Cattori

Gomes-Keller

, et al.: 2005, Quantitation of feline leukaemia virus viral and proviral loads by TaqMan real-time polymerase chain reaction. J Virol Methods 130:124–132.

30.

Tandon

Catorri

Willi

, et al.: 2007, Copy number polymorphism of endogenous feline leukemia virus-like sequences. Mol Cell Probes 21:257–266.

31.

Torres

O’Halloran

Larson

, et al.: 2008, Development and application of a quantitative real-time PCR assay to detect feline leukemia virus RNA. Vet Immunol Immunopathol 123:81–89.

32.

Wittwer

Reed

Gundry

, et al.: 2003, High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 49:853–860.

33.

Dhillon

, et al.: 2001, An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 29:E88.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.20 MB

Development of a multiplex amplification refractory mutation system reverse transcription polymerase chain reaction assay for the differential diagnosis of Feline leukemia virus vaccine and wild strains

Abstract

Keywords

Introduction

Materials and methods

Sample collection and analysis

P27 immunochromatography analysis

Isolation of DNA and RNA from white blood cells

Polymerase chain reaction primers

Polymerase chain reaction reverse transcription PCR, and cloning of sequence

In vitro transcription of FeLV plasmid

Amplification refractory mutation system RT-PCR and ARMS qRT-PCR combined with high-resolution melt analysis

Sensitivity and specificity of ARMS RT-PCR and ARMS qRT-PCR

Phylogenetic analysis

Results

Samples detected by PCR and p27 immunochromatography and sequence analysis for the design of ARMS RT-PCR primers

Sensitivity of ARMS RT-PCR and ARMS qRT-PCR

Specificity of ARMS RT-PCR and ARMS qRT-PCR

Clinical samples detected by ARMS RT-PCR and ARMS qRT-PCR

Phylogenetic analysis of FeLV vaccine and FeLV TW strains

Discussion

Footnotes

Acknowledgements

a.

b.

c.

d.

e.

f.

g.

h.

i.

j.

k.

l.

Declaration of conflicting interests

Funding

References

Supplementary Material